 Home > Active Ingredient News > Antitumor Therapy > Eur Urol: Differential Response Analysis of Different Molecular Subtypes of Urothelial Carcinoma to Neoadjuvant Chemotherapy

Eur Urol: Differential Response Analysis of Different Molecular Subtypes of Urothelial Carcinoma to Neoadjuvant Chemotherapy

 Last Update: 2021-12-24
 Source: Internet
 Author: User

Tags

molecular cancer therapeutics

different atmospheres

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Neoadjuvant chemotherapy is one of the few treatment options with the highest level of evidence in the treatment of myometrial invasive bladder cancer (MIBC), but before radical cystectomy (RC) treatment, the use of neoadjuvant chemotherapy is still less
.

The reason for the low use rate of neoadjuvant chemotherapy is that the treatment-related toxicity and absolute survival benefit are not high, ranging from 5% to 10%

It has not been used clinically to reduce biomarkers over-treatment of non-responders, represents a major challenge to medical needs and a study of unmet has not been used clinically to reduce biomarkers nonresponders over-treatment, representing a Unmet medical needs and major research challenges

Currently, for myometrial invasive bladder cancer (MIBC), there are no tissue biomarkers that can be used to clinically predict the response to neoadjuvant chemotherapy
.

Recently, researchers from Sweden published an article on the "Eur Urol" magazine, investigated how different molecular subtypes influence pathological response and students before preoperative chemotherapy of cisplatin deposit rate
.

We investigated how different molecular subtypes influence pathological response and students before preoperative chemotherapy of cisplatin deposit rate investigated how different molecular subtypes influence pathological response and students before preoperative chemotherapy of cisplatin deposit rate deposit

The researchers used tumor transcriptome analysis and immunostaining to classify a retrospective cohort of 149 patients
.

A cohort of only radical cystectomy and public data sets were used for comparison and external verification

The results showed that after neoadjuvant chemotherapy and radical cystectomy, patients with genomic instability (GU) and epithelial (Uro) tumors had a higher proportion of complete pathological responses (16/31 [52%] and 17/54, respectively [ 31%]), and the proportion of complete pathological responses in patients with the basal/squamous (Ba/Sq) subtype was 5/21 (21%)
.

After adjusting the clinical stage, compared with Ba/Sq tumors, molecular subtypes were compared with GU tumors (hazard ratio [HR] 0.

Molecular subtypes and clinical staging are related to cancer-specific survival of neoadjuvant chemotherapy

In summary, the luminal urothelial carcinoma subtype has a stronger response to neoadjuvant chemotherapy based on cisplatin
.

The second-generation subtype-specific biomarkers, such as SPP1, may be a direction for the development of more precise treatments in MIBC neoadjuvant chemotherapy

The luminal urothelial carcinoma subtype has a stronger response to neoadjuvant chemotherapy based on cisplatin

Original source:

Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten et al.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.